Literature DB >> 2964516

Technetium-99m MAG3, a comparison with iodine-123 and iodine-131 orthoiodohippurate, in patients with renal disorders.

R A Jafri1, K E Britton, C C Nimmon, K Solanki, A Al-Nahhas, J Bomanji, J Fettich, L A Hawkins.   

Abstract

A Phase I study in 12 patients with renal disorders compared the simultaneous clearances of 99mTc-labeled mercaptoacetyltriglycine (MAG3) and 131I-labeled orthoiodohippurate (OIH). The ratio of MAG3 to OIH clearance was 0.61 +/- 0.08 as a result of its smaller volume of distribution, ratio 0.65 +/- 0.09, for the clearance half-lives were similar, ratio 1.09 +/- 0.12. A Phase II study performed serially in 20 patients with equal doses of [99mTc]MAG3 and [123I]OIH gave images of equal quality. The relative renal functions were highly correlated (r = 0.97, p less than 0.001) and transit time analyses gave good correlations: parenchymal transit time index r = 0.81, p less than 0.05. We conclude that [99mTc]MAG3 has some advantages over [99mTc]DTPA and is a suitable replacement for [123I]hippuran in routine renal imaging, relative function, and transit time studies, but not for the accurate estimation of the renal plasma flow.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2964516

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

1.  Comparison of technetium-99m MAG3 kit formulations in Europe and the USA.

Authors:  J C Hung
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  Quantification of renal haemodynamics with radionuclides.

Authors:  A M Peters
Journal:  Eur J Nucl Med       Date:  1991

Review 3.  A brief overview of metal complexes as nuclear imaging agents.

Authors:  Douglas S MacPherson; Kimberly Fung; Brendon E Cook; Lynn C Francesconi; Brian M Zeglis
Journal:  Dalton Trans       Date:  2019-10-07       Impact factor: 4.390

Review 4.  The development of new radiopharmaceuticals.

Authors:  K E Britton
Journal:  Eur J Nucl Med       Date:  1990

5.  What does protein binding of radiopharmaceuticals mean exactly?

Authors:  O Jeghers; A Piepsz; H R Ham
Journal:  Eur J Nucl Med       Date:  1990

6.  An investigation of factors that might influence the radiochemical purity and stability of 99mTc-MAG3.

Authors:  A M Millar; L M O'Brien
Journal:  Eur J Nucl Med       Date:  1990

7.  Re(CO)3([18F]FEDA), a novel 18F PET renal tracer: Radiosynthesis and preclinical evaluation.

Authors:  Malgorzata Lipowska; Nashwa Jarkas; Ronald J Voll; Jonathon A Nye; Jeffrey Klenc; Mark M Goodman; Andrew T Taylor
Journal:  Nucl Med Biol       Date:  2017-12-27       Impact factor: 2.408

8.  99mTc(CO)3(NTA) and 131I-OIH: comparable plasma clearances in patients with chronic kidney disease.

Authors:  Andrew T Taylor; Malgorzata Lipowska; Hui Cai
Journal:  J Nucl Med       Date:  2013-02-19       Impact factor: 10.057

9.  First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent.

Authors:  C G Van Nerom; G M Bormans; M J De Roo; A M Verbruggen
Journal:  Eur J Nucl Med       Date:  1993-09

10.  Initial Evaluation of (99m)Tc(CO)3(ASMA) as a Renal Tracer in Healthy Human Volunteers.

Authors:  Malgorzata Lipowska; Jeffrey Klenc; Russell D Folks; Andrew T Taylor
Journal:  Nucl Med Mol Imaging       Date:  2014-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.